NCT00190983View on ClinicalTrials.gov

A Trial for Patients With Advanced/Recurrent Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Cervical Intraepithelial NeoplasiaUterine NeoplasmsGenital Neoplasms, Female
Interventions
DRUG

Pemetrexed

Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.

Trial Locations (1)

Unknown

Gynecologic Oncology Group 215-854-0770, Philadelphia

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

Eli Lilly and Company

INDUSTRY

NCT00190983 - A Trial for Patients With Advanced/Recurrent Cervical Cancer | Biotech Hunter | Biotech Hunter